Indonesia IVD Market Analysis

 
   Single User - $4,200
   Site License (one location, 10 users) - $6,300
   Corporate License - $8,400


Published Jul 19, 2017 | 217 Pages | Pub ID: KLI15417339

Indonesia IVD Market Analysis

Visit our 'In Vitro Diagnostics' curated page for complete industry coverage.

Indonesia is the 4th largest country in the world in terms of population after China, India, and USA and an important and prospective market for diagnostics and medical device manufacturers. This Kalorama Information report was produced by Malaysia-based analysts and analysts operating in Indonesia. Market analyses in this report cover Indonesian markets for life science and clinical applications of in vitro diagnostics (IVD) technology. Indonesia IVD Market Analysis provides market segmentation, discusses healthcare and regulatory trends, and examines in vitro diagnostics companies participating in Indonesia's market.

Data Points Include:

  • Sales of Rapid Tests for Infectious Diseases by Category, Indonesia, 2017-2022 (HIV; STDs; Hepatitis [HBV, HCV, etc.]; Other [includes Dengue, Malaria, Typhoid, RSV, Filariasis, etc.]; Rapid Tests-Infectious Diseases, Total)
  • Microbiology Sales in Indonesia, 2017-2022 (Rapid Tests-Infectious Diseases; Lab-based Immunoassays - Infectious Diseases; Molecular Diagnostics - Microbiology; Other [includes supplies, reagents, etc.]; Microbiology, Total)
  • Hematology Sales by Category, Indonesia, 2017-2022 (Hematology Systems; Hematology POC; Other [Digital imaging, analysis software, etc.]; Hematology, Total)
  • Indonesia Clinical Chemistry Market by Category, 2017-2022 (General Chemistry; Blood Gas Analyzers; Critical Care POC; Clinical Chemistry, Total)
  • Indonesia POC Market by Category, 2017-2022 (POC-Diabetes; POC-OTC/Self-Testing, Other; POC-OTC/Self Testing, Total; Cardiac Markers; DOA/Toxicology; Other; POC-Professional, Total; POC, Total)
  • Indonesia Immunoassay Market (Non-Infectious) by Category, 2017-2022 (Diabetes; Cardiac markers; Other [Cancer Markers, DOA tests; cholesterol, RIAs for thyroid, hormones, endocrine markers, etc.]; Total, Lab-based Immunoassays - Non-Infectious; DOA testing - rapid tests; Cancer markers - Rapid tests; Cardiac markers - Rapid tests; Others [Pregnancy, Cancer markers, etc.]; Total, POC - Immunoassays - Non-Infectious; Total – Immunoassays - Non-Infectious)
  • Blood Testing and Typing Sales by Category (ABO Grouping, Immunoassays [ELISA and Rapid Tests], NAT), Indonesia, 2017-2022
  • Hemostasis Sales by Category (Lab-based Coagulation Tests, POC Coagulation Tests), Indonesia, 2017-2022
  • Histology Sales by Category (Traditional Non-Pap Stains, Pap Tests, HPV, Other [includes ISH, IHC, Digital Imaging, CTC, and Flow Cytometry]), Indonesia, 2017-2022
  • Major Diseases and Demand for Lab-based Immunoassay Diagnostics in Indonesia, 2017-2022 (HIV; STDs; Hepatitis [HBV, HCV, etc.]; Other [includes Dengue, Malaria, Typhoid, RSV, Filariasis, etc.]; Lab-based Immunoassays - Infectious Diseases, Total)
  • Popular Rapid Test Brands and Their Distributors in Indonesia
  • STD Test Costs at Selected Clinics and Hospitals in Indonesia
  • Total IVD Market in Indonesia by Segment (Microbiology, Hematology, Clinical Chemistry, POC, Immunoassays - Non-Infectious Diseases, Blood Testing and Typing, Urinalysis, Coagulation, Histology, Others [includes Molecular Diagnostics (Non-Infectious), Supplies, Reagents, IT, Imaging, Automation, etc.]), 2017-2022
Indonesia's market for in vitro diagnostics is not without challenges. However, Indonesia’s healthcare sector is set to grow rapidly in the next five years through various initiatives by government. The most important initiative is the universal health coverage (UHC) plan, which is locally known as JKN, announced in 2014. Under UHC, the government is targeting to ensure health insurance available for entire population of the country by 2019. UHC implementation is progressing at a fast pace, with investments from both private and public sectors.

Indonesian Healthcare Market Data:

  • Indonesia Healthcare Expenditure, 2000-2014 (Total Health Expenditure as % of GDP, Public Health Expenditure, Private Health Expenditure)
  • General and Specialty Hospitals in Indonesia, 2011-2015
  • Community Healthcare Centers (CHCs) in Indonesia, 2011-2015
  • Distribution of Puskesmas (CHCs) in Indonesia across 34 Provinces
  • Selected General and Specialty Hospitals in Indonesia
  • Selected Leading Private Hospitals in Indonesia, by Province
  • Selected Private Laboratories in Indonesia
  • Indonesia Healthcare Spending Compared to Southeast Asia Neighbors (New Zealand, Japan, Australia, South Korea, Vietnam, China, Singapore, India, Malaysia, Thailand)
Options for a Foreign IVD Company to Enter the Indonesian MarketIn the Indonesia IVD market, foreign IVD companies are banned from making any direct sales. Only local distribution companies, who have distribution licenses, can engage in IVD sales in the country. Therefore, assistance of a local legal firm is the best way for a foreign company to set up its operations in Indonesia. The report examines the options available to a foreign IVD company looking to enter the Indonesian market. These include:
  • Opening an Affiliated Branch Office in Indonesia
  • Selecting a Suitable Exclusive Distributor
  • Setting up Original Equipment Manufacturer (OEM) Operations; Investing in Local Manufacturing within 3 Years
Via three case studies, business strategies adopted by multinational companies (MNCs) are examined as well.

Also included are other valuable resources regarding the regulation of IVD devices and distribution within the framework of the Indonesian IVD market:
  • Selected Foreign Companies and Their Key Distributors in Indonesia
  • Classification of Medical Devices in the Indonesian Healthcare Market
  • Processes for Distribution License, Company and Product Registrations
  • Licenses Required for IVD Distribution in Indonesia
  • Indonesia Investment Coordinating Board (BKPM) Offices

Competitive Analysis

In the Indonesian healthcare market, rapidly increasing expenditure trends hint at new market opportunities for market players and investors. Indonesia IVD Market Analysis provides information on the major players in IVD market sub-segments, including:
  • Major Players in the Indonesian Hematology Market
  • Major Players in the Indonesian Clinical Chemistry Market
  • Major Players in the Indonesian Urinalysis Market
  • Major Players in the Indonesian Coagulation Market
  • Major Players in the Indonesian Histology Market
  • Distribution of Blood Centers in Indonesia, by Province
Indonesia IVD Market Analysis provides as well profiles of IVD companies, private labs, and distributors operating in the Indonesian IVD Market.

IVD Company Profiles Including:

  • Abbott Laboratories
  • Alere
  • Arkray Healthcare
  • Beckman Coulter
  • Becton, Dickinson and Company (BD)
  • bioMerieux
  • Bio-Rad
  • Cellavision
  • Cepheid
  • Critical Diagnostics
  • DiaSorin S.p.A.
  • EKF Diagnostics
  • ERBA Diagnostics
  • HemoCue AB
  • Hologic, Inc.
  • Horiba, Ltd.
  • Instrumentation Laboratory Company
  • Luminex Corporation
  • Mindray Medical International Limited
  • Nihon Kohden Corporation
  • Ortho Clinical Diagnostics
  • Qiagen N.V.
  • Radiometer Medical ApS
  • Randox Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Tosoh Corporation
  • Trinity Biotech
  • Laboratorium Klinik Utama Bio Medika
  • PT Cito Putra Utama
  • PT Kimia Farma Diagnostika
  • Laboratorium Klinik Pramita
  • PT Prodia Widyahusada Tbk

Methodology

The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas where IVD assays are used.
CHAPTER ONE: EXECUTIVE SUMMARY

INTRODUCTION
Figure 1-1: Map of Indonesia, with Provinces

Figure 1-2: Total Population of Indonesia (2000-2016)

Table 1-1: GDP Growth in Indonesia, 2012-2015
HEALTH STATUS OF INDONESIANS

HEALTHCARE DELIVERY SYSTEM

REGULATION OF IVD DEVICES AND DISTRIBUTION

SCOPE AND METHODOLOGY

SIZE AND GROWTH OF THE IVD MARKET

Figure 1-3: IVD Market in Indonesia, 2017 and 2022
CHAPTER TWO: INDONESIA - A GROWING IVD MARKET

HEALTHCARE EXPENDITURE IN INDONESIA
Figure 2-1: Growth of Health Expenditure per Capita (USD) in Indonesia, 2000-2014

Figure 2-2: Growth of Health Expenditure per Capita in PPP Terms (USD), Indonesia, 2000-2014
HEALTH INDICATORS IN INDONESIA
Figure 2-3: Top 10 Causes of Death in Indonesia

Table 2-1: Life Expectancy and Mortality Rates in Indonesia, 2000-2014 (Life Expectancy, Total; Life Expectancy at Birth, Male; Life Expectancy at Birth, Female; Total Mortality Rate, Adult, Male; Total Mortality Rate, Adult, Female)
PREVALENT INFECTIOUS DISEASES IN INDONESIA
Tuberculosis (TB)

Table 2-2: Assessment of TB Burden in Indonesia, WHO

Table 2-3: Pulmonary Tuberculosis Cases by Province, Indonesia

HIV/AIDS

Table 2-4: The Number of New Cases of HIV and AIDS between 2011 and 2015, Indonesia

Table 2-5: HIV and AIDS Cases in Indonesia, by Province

Malaria

Table 2-6: Incidence of Malaria in Indonesia, by Province

Dengue

Table 2-7: Dengue Hemorrhagic Fever (DHF) Cases in Indonesia, by Province

Filariasis

Table 2-8: Filariasis in Indonesia, 2011-2015

Table 2-9: Filariasis Cases in Indonesia, by Province, 2012-2014


Leptospirosis

Table 2-10: Leptospirosis Cases in Indonesia, by Province, 2011-2015

Typhoid

Table 2-11: Typhoid Prevalence in Indonesia, by Province

Human Papilloma Virus (HPV)
INDONESIAN HEALTHCARE INDUSTRY LANDSCAPE
Figure 2-4: Healthcare Delivery in Indonesia

Healthcare Delivery System

Public Healthcare System: General and Specialty Hospitals

Table 2-12: General and Specialty Hospitals in Indonesia, 2011-2015

Public Healthcare System: Community Healthcare Centers (CHCs/Puskesmas)

Table 2-13: Community Healthcare Centers in Indonesia, 2011-2015


Table 2- 14: Distribution of Puskesmas (CHCs) in Indonesia across 34 Provinces

Hospital Classification in Indonesia

Table 2-15: Selected General and Specialty Hospitals in Indonesia

Private Healthcare System

Table 2-16: Selected Leading Private Hospitals in Indonesia, by Province


Private Labs in Indonesia

Table 2-17: Selected Private Laboratories in Indonesia

FINANCIAL ASPECTS OF THE HEALTHCARE INDUSTRY IN INDONESIA

Table 2-18: Indonesia Healthcare Spending Compared to Southeast Asia Neighbors (New Zealand, Japan, Australia, South Korea, 

Vietnam, China, Singapore, India, Malaysia, Thailand)

Table 2-19: Indonesia Healthcare Expenditure, 2000-2014 (Total Health Expenditure as % of GDP, Public Health Expenditure, Private 
Health Expenditure)

Implementation of UHC

Private Health Insurance
E-CATALOGUE PRICING SYSTEM

KEY MARKET DRIVERS OF THE INDONESIAN HEALTHCARE MARKET

KEY CHALLENGES IN THE INDONESIAN HEALTHCARE MARKET
Uncertainty among Private Insurers

Rigid Reference Model Hampering Healthcare Accessibility

Limited Access to Quality Healthcare Facilities

Gap between Supply and Demand of Medical Professionals

Impact of the E-Catalogue Pricing System


Impact of Government’s Policies on Foreign Direct Investments (FDI)

Logistics Challenges
IVD PRODUCT REGULATION IN INDONESIA
Table 2-20: Classification of Medical Devices
IMPORTANT FACTORS TO CONSIDER WHILE CHOOSING AN IVD DISTRIBUTOR IN INDONESIA
Trade-Off between Small and Big Distributors
Table 2-21: Selected Foreign Companies and Their Key Distributors in Indonesia
PROCESSES FOR DISTRIBUTION LICENSE, COMPANY AND PRODUCT REGISTRATIONS
Company/Product Registration
Table 2-22: Licenses Required for IVD Distribution in Indonesia
REGULATORY TRENDS AND INSIGHTS RELEVANT FOR THE IVD SECTOR
Market Transition to E-Catalogue and Related Regulations
REGULATIONS FOR FOREIGN DIRECT INVESTMENTS (FDI)
Table 2-23: Indonesia Investment Coordinating Board (BKPM) Offices
SETTING UP A COMPANY IN INDONESIA
Table 2-24: Options for a Foreign IVD Company to Enter the Indonesian Market

Assessing Option 1: Opening an Affiliated Branch Office in Indonesia

Assessing Option 2: Select a Suitable Exclusive Distributor

Assessing Option 3: Set up OEM Operations; Invest in Local Manufacturing within 3 years

BUSINESS STRATEGIES ADOPTED BY MULTINATIONAL COMPANIES (MNCS): CASE STUDIES
Roche

bioMerieux

Thermo Fisher Scientific

Conclusion
CHAPTER THREE: IVD MARKET ANALYSIS

MICROBIOLOGY

LFIA Tests (Rapid Tests) for Infectious Diseases
Table 3-1: Sales of Rapid Tests for Infectious Diseases by Category, Indonesia, 2017-2022 (HIV; STDs; Hepatitis [HBV, HCV, etc.]; Other [includes Dengue, Malaria, Typhoid, RSV, Filariasis, etc.]; Rapid Tests-Infectious Diseases, Total)

Table 3-2: Popular Rapid Test Brands and Their Distributors in Indonesia
Lab-based Immunoassays for Infectious Diseases

Table 3-3: STD Test Costs at Selected Clinics and Hospitals in Indonesia

Table 3-4: Major Diseases and Demand for Lab-based Immunoassay Diagnostics in Indonesia, 2017-2022 (HIV; STDs; Hepatitis [HBV, HCV, etc.]; Other [includes Dengue, Malaria, Typhoid, RSV, Filariasis, etc.]; Lab-based Immunoassays - Infectious Diseases, Total)
ID/AST
Molecular Diagnostics

Table 3-5: Microbiology Sales in Indonesia, 2017-2022 (Rapid Tests-Infectious Diseases; Lab-based Immunoassays - Infectious Diseases; Molecular Diagnostics - Microbiology; Other [includes supplies, reagents, etc.]; Microbiology, Total)
HEMATOLOGY
Table 3-6: List of Major Players in the Indonesian Hematology Market

Table 3-7: Hematology Sales by Category, Indonesia, 2017-2022 (Hematology Systems; Hematology POC; Other [Digital imaging, analysis software, etc.]; Hematology, Total)
CLINICAL CHEMISTRY
Table 3-8: List of Major Players in the Indonesian Clinical Chemistry Market

Table 3-9: Clinical Chemistry Analyzer Sales by Category, Indonesia, 2017-2022 (General Chemistry; Blood Gas Analyzers; Critical Care POC; Clinical Chemistry, Total)

POINT-OF-CARE TESTS

POC - OTC/ Self-Testing

POC – Professional-Testing

POC Hand-Held Devices

POC Bench-Top Analyzers

Table 3-10: POC Sales by Category, Indonesia, 2017-2022 (POC-Diabetes; POC-OTC/Self-Testing, Other; POC-OTC/Self Testing, Total; 
Cardiac Markers; DOA/Toxicology; Other; POC-Professional, Total; POC, Total)

IMMUNOASSAYS

Point-of-Care (POC) Immunoassays

Immunoassays for Non-Infectious Diseases

Table 3-11: Immunoassay (Non-Infectious) Sales by Category, Indonesia, 2017-2022 (Diabetes; Cardiac markers; Other [Cancer 
Markers, DOA tests; cholesterol, RIAs for thyroid, hormones, endocrine markers, etc.]; Total, Lab-based Immunoassays - Non-
Infectious; DOA testing - rapid tests; Cancer markers - Rapid tests; Cardiac markers - Rapid tests; Others [Pregnancy, Cancer markers, 
etc.]; Total, POC - Immunoassays - Non-Infectious; Total – Immunoassays - Non-Infectious)

BLOOD TESTING AND TYPING

Table 3-12: Distribution of Blood Centers in Indonesia, by Province

Non-Standardized Evaluation Protocol

Table 3-13: Blood Testing and Typing Sales by Category (ABO Grouping, Immunoassays [ELISA and Rapid Tests], NAT), Indonesia, 
2017-2022

URINALYSIS

Table 3-14: List of Major Players in the Indonesian Urinalysis Market

COAGULATION

Table 3-15: List of Major Players in the Indonesian Coagulation Market

Table 3-16: Hemostasis Sales by Category (Lab-based Coagulation Tests, POC Coagulation Tests), Indonesia, 2017-2022

HISTOLOGY

Table 3-17: List of Major Players in the Indonesian Histology Market

Table 3-18: Histology Sales by Category (Traditional Non-Pap Stains, Pap Tests, HPV, Other [includes ISH, IHC, Digital Imaging, CTC, 
and Flow Cytometry]), Indonesia, 2017-2022

TOTAL IVD MARKETS IN INDONESIA

Table 3-19: Total IVD Market in Indonesia by Segment (Microbiology, Hematology, Clinical Chemistry, POC, Immunoassays - Non-
Infectious Diseases, Blood Testing and Typing, Urinalysis, Coagulation, Histology, Others [includes Molecular Diagnostics (Non-
Infectious), Supplies, Reagents, IT, Imaging, Automation, etc.]), 2017-2022

CHAPTER FOUR: IVD COMPANIES, PRIVATE LABS AND DISTRIBUTOR PROFILES

IVD COMPANY PROFILES

Abbott Laboratories

Alere

Arkray Healthcare

Beckman Coulter

Becton, Dickinson and Company (BD)

bioMerieux

Bio-Rad

Cellavision

Cepheid

Critical Diagnostics

DiaSorin S.p.A.

EKF Diagnostics

ERBA Diagnostics

HemoCue AB

Hologic, Inc.

Horiba, Ltd.

Instrumentation Laboratory Company

Luminex Corporation

Mindray Medical International Limited

Nihon Kohden Corporation

Ortho Clinical Diagnostics

Qiagen N.V.

Radiometer Medical ApS

Randox Laboratories

Roche Diagnostics

Siemens Healthineers

Sysmex Corporation

Thermo Fisher Scientific

Tosoh Corporation

Trinity Biotech

LEADING PRIVATE LABS IN INDONESIA

Laboratorium Klinik Utama Bio Medika

PT Cito Putra Utama

PT Kimia Farma Diagnostika

Laboratorium Klinik Pramita

PT Prodia Widyahusada Tbk

PROFILES OF SELECTED IVD DISTRIBUTORS IN INDONESIA

Table 4-1: Profiles of Selected IVD Distributors in Indonesia




In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.